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knowledge of pathogen virulence may allow us to implement
therapeutic strategies directed to speciﬁc virulence factors.
As an example, the production of exotoxins from CA-MRSA is
considered a primary virulence mechanism of this organism
in patients with necrotizing pneumonia.29 Based on this
understanding, it has been suggested that blocking protein
synthesis in CA-MRSA may improve patient outcomes.30
A better understanding of the host response may allow us
to manipulate the deleterious immune response that occurs
in some patients with CAP. Immune modulation in hospital-
ized patients with severe CAP through the use of steroids has
been evaluated, but the results remain controversial.31,32
Several retrospective studies have suggested a beneﬁt of
macrolide antibiotics in patients with severe CAP due to their
role as immunomodulators.33–35
The primary approach to improve outcomes in hospital-
ized patients with CAP continues to be the optimal use of
antimicrobials. The literature indicates that optimal antimi-
crobial use in hospitalized patients with CAP requires the
practice of a series of strategies that can be summarized as a
CAP antimicrobial care bundle. In the prevention and man-
agement of health care associated infections, the concept of a
care bundle indicates a set of interventions that, if grouped
and implemented together, promote best outcomes with a
greater impact than if performed individually. The timing of
CAP antimicrobial bundle interventions is summarized
in ►Fig. 6. After a patient arrives at the emergency depart-
ment with signs and symptoms of lower respiratory tract
infection, there is an initial period when the history, physical
examination, laboratory evaluation, and chest x-ray are
obtained. Once the diagnosis of CAP is performed, a full
microbiological workup should be obtained followed by
initiation of antimicrobial therapy. The time between arrival
at the emergency department and delivery of antimicrobials
is deﬁned as the antibiotic timing. Because the literature
indicates that prolonged antibiotic timing is associated with
worse outcomes, initial antibiotics should be administered
soon after the clinical diagnosis of CAP is performed.24 Initial
antimicrobial therapy can be deﬁned as empirical therapy or
targeted therapy. Empirical therapy is performed with broad
spectrum antibiotics that cover the most likely pathogens.
Optimal empirical therapy in regard to antibiotic selection
and dose is recommended by national organizations in most
countries. Empirical therapy in concordance with guidelines
is associated with improved patient survival.36,37 As new
point of care microbiological tests are available to diagnose
the etiology of CAP during the initial patient evaluation, the
possibility of initiating antimicrobial therapy directed to the
pathogen causing CAP is now possible. This approach, using
initial therapywith narrow spectrum antibiotics, is deﬁned as
targeted therapy or pathogen-directed therapy. Targeted
therapy may be associated with decreased antibiotic toxicity,
decreased collateral damage, and decreased development of
colonization or infection with drug-resistant organisms.
The initial dose of antimicrobials should be given in the
emergency department before hospital admission. One im-
portant decision at the time of hospitalization is the site of
hospital care. Patients can be hospitalized to a medical ward
or a medical ICU. Data from the CAPO study indicate that 12%
of hospitalized patients with CAP are admitted directly to the
medical ICU, whereas 5% are admitted to the medical ward
and later transferred to the medical ICU. Mortality for pa-
tients admitted directly to the ICU was 22% compared with
33% for patients admitted to the medical ward and later
transferred to the ICU (p ¼ 0.001). CAPO data suggesting
that delayed ICU admission is associated with increased
mortality have been previously reported by other
investigators.38
After hospitalization, the patient should be evaluated
daily. The day that the patient reaches clinical stability,
intravenous antibiotics can be switched to oral antibiotics,
a practice deﬁned as switch therapy. If results of initial
microbiological cultures deﬁned the etiology of CAP, empiri-
cal broad spectrum therapy should be changed to therapy
directed to the pathogen causing CAP, a practice deﬁned as
deescalation of therapy. Discontinuation of antibiotics can
occur in some patients soon after the patient reaches clinical
stability. The sequential optimal application of the CAP
antimicrobial bundle will allow for a shorter time to clinical
stability, a decreased duration of hospitalization, and im-
proved patient morbidity andmortality. The implementation
of CAP antimicrobial bundles at the local hospital level can be
evaluated with the use of quality indicators. Some aspects of
the CAP antimicrobial bundle are evaluated in the CAPO
international study using quality indicators. Evaluation of a
microbiologicalworkup before initiation of antibiotic therapy
indicates that blood cultures are obtained in 67% of hospital-
ized patients with CAP, and sputum cultures are obtained in
52% of hospitalized patients with CAP. The switch from
intravenous to oral antibiotics on the day that the patient
reaches clinical stability is performed in 46% of the patients.
Several of the CAPO quality indicator data suggest the need to
improve CAP antimicrobial bundle implementation in most
regions of the world.
Clinical Outcomes Weeks after Hospitalization
After hospital discharge, patients with CAP regularly have a
follow-up clinic appointment within 4weeks. During the ﬁrst
month following the diagnosis of CAP, some patients may
Figure 6 Components of the antimicrobial bundle for management of
patients with pneumonia.
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Early antibiotics and outcome 
Author n Setting Odds Ratio (death) 
Gaieski (Crit Care Med 2010; 38:1045) 261 ED (Shock) First hour – OR 0.30 
Daniels (Emerg Med J 2010; doi:10.1136) 567 Whole hospital 
First hour – OR 0.62 
 
Kumar (Crit Care Med 2006;34:1589) 2154 ED (Shock) First vs second hour – OR 0.59 
Appelboam (Crit Care 2010;14:50) 375 Whole hospital First hour –OR 0.74 
Levy (Crit Care Med 2010; 38:1) 15022 Multi-centre 
First 3h – OR 0.86 
 
Barie (Surg Infect (Larchmt) 2005;6:41) 356 Surgical ICU Per hour delay – 1.021 
Ferrer (Crit Care Med 2014;42:1749) 17990 Multi-centre 
Progressive increase in risk per 
hour (1.07-1.52) 
Jalili (Acta Med Iran 2013; 51:454) 145 ED (sepsis) First 2h – OR 0.44 
No difference in a metanalysis (11 studies included). OR 1.16 
Sterling Crit Care Med. 2015;43:1907 
Author n Setting Odds Ratio (death) 
De Groot (Critical Care 2015; 19:194) 1168 3 ED 
No difference independent of 
PIRO score 
Hranjec (Lancet Infect Dis 2012;12:774) 201 
Surgical ICU: Before-
after 
Aggressive antibiotic therapy – 
OR for mortality 2.5 
 
Puskarich (Crit Care Med 2011;39:12066) 372 
Hospital-acquired 
surgical infections 
No difference in mortality up to 
6h after diagnostic 
Villela (Am J Emerg Med 2014;32:7) 184 ED admitted to the ICU 
No improvement with decrease 
in time to antibiotics (5h to 3h) 
Pelletier(Surg Infec  (Larch) 1999;134:1300) 372 Surgical patients No difference h,>12h, >24h 
Castellanos-Ortega  (Crit Care Med 
2010;38:1036) 
480 ED: Before-after Early antibiotics OR 0.68, p=0.11 
Davies (Shock 2014;42:185) 7158 Surgical patients 
Inappropriate vs. appropriate OR 
1.0 
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and more than 5 hours for further assessment of the effect of 
hourly delays to antibiotic administration from severe sepsis/
shock recognition. The groups contained 848 deaths of 2,318 
patients in the less than 1-hour group, 471 deaths of 1,298 
patients in the 1- to 2-hour group, 323 deaths of 853 patients 
in the 2- to 3-hour group, 245 deaths of 615 patients in the 
3- to 4-hour group, 193 deaths of 453 patients in the 4- to 5-hour 
group, and 1,537 deaths of 2,386 patients in the more than 
5-hour group. We observed no statistical significant increased 
mortality in the pooled ORs 
for each hourly incremental 
delay in antibiotic administra-
tion from severe sepsis/shock 
recognition (Table 5).
DISCUSSION
The SSC international guide-
lines for the management of 
severe sepsis and septic shock 
recommend administer-
ing antibiotics within 1 hour 
of recognition and within 
3 hours of ED triage (13). 
Using the available published 
data, our results indicate that 
in patients with severe sepsis 
and septic shock, antibiotic 
administration within 3 hours 
of ED triage and/or within 1 
hour of shock recognition is 
not associated with significant 
improvement in mortality. 
Our findings do not support 
the SSC guideline recommen-
dations on timing of antibi-
otic administration and raise 
concern about the use of time 
to antibiotic administration 
as currently recommended as 
a specific metric of treatment 
quality in sepsis care (13).
The recognition and treat-
ment of severe sepsis and septic 
shock remain a complex and 
challenging burden for clini-
cians with a persistently high 
mortality rate (1, 2, 12). In the 
past 15 years, research has sug-
gested that an early structured 
approach to recognition and 
treatment of sepsis improves 
outcomes likely due to a com-
bination of factors includ-
ing heightened recognition 
or awareness, early reversal of 
microcirculatory or endothe-
lial dysfunction, reversal of hypoperfusion, and/or eradication 
of infectious nidus (3–5, 7). However, the results of studies 
focusing on the impact of timing of antibiotic administration 
have been inconsistent (8, 9, 11, 14, 19).
While it is recognized that failure to administer effective 
antimicrobial therapy will at some time point be detrimental to 
patient outcomes, the exact time frame when this shift begins 
to occur remains unknown. Furthermore, no randomized clin-
ical trials examine the impact of the timing of antibiotics on 
Figure 2. Summary of forest plots. A, Pooled odds ratios for mortality and time to antibiotics in less than or 
more than 3 hr from triage time. B, Pooled odds ratios for mortality and time to antibiotics in less than or more 
than 1 hr from severe sepsis/shock recognition.
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infection (probable/definite) was associated with a lower
mortality (SHR 0.81; 95 % CI 0.67–0.97). This means that
patients with a confirmed infection diagnosis actually have
a lower mortality rate than patients with an unconfirmed
infection or an alternative diagnosis. Cause-specific ana-
lysis revealed that this reduction was caused by a direct ef-
fect on death (CSHR 0.73; 95 % CI 0.61–0.89), and not by
the indirect effect on a longer ICU length of stay (CSHR
0.93; 95 % CI 0.85–1.02). In subgroup analyses, the mor-
tality hazard for each hospital was similar (hospital A:
SHR 0.80, 95 % CI 0.62–1.03; hospital B: SHR 0.85, 95 %
CI 0.63–1.13). These estimates were similar when restrict-
ing our analysis to cases with none or definite infections
only (SHR 0.75, 95 % CI 0.55–1.01). Furthermore, the
prevalence of the adult respiratory distress syndrome, the
prevalence of acute kidney injury, and the length of stay
significantly increased with greater infection likeli-
hoods (p <0.001), whereas the occurrence of ICU-
acquired infections did not (p = 0.36) (Fig. 3). In the
main subgroups of presumed infection sites, the in-
fection plausibility was not associated with outcome
parameters in this crude analysis, except for pulmon-
ary infections.
Discussion
We determined the accuracy of the infection diagnosis
made by clinicians in the context of presumed sepsis
upon admission to the ICU and found that up to 43 %
of patients treated for sepsis were unlikely to have had
an infection on post-hoc assessment. Although the ac-
curacy of the infection diagnosis increased with increas-
ing severity of disease, a considerable proportion of
patients with severe sepsis and septic shock still had at
most a possible infection. These results show that mak-
ing an accurate infection diagnosis upon ICU admission
in patients with suspected sepsis is difficult in many
cases.
Our study is the first prospective comparison of sepsis
diagnoses made by ICU physicians and post-hoc analyses
of infection likelihoods based on strict diagnostic cri-
teria, revealing that the true incidence of sepsis upon
ICU admission is probably overestimated. Only few pre-
vious studies have specifically investigated the accuracy
of infection diagnoses in patients with suspected sepsis
in the ICU. A French study found that 49 % of patients
were potentially unnecessarily treated for a new infec-
tion on the ICU [16]. This finding was based on the level
of microbiological evidence and not on well-defined
diagnostic criteria, however, making it difficult to appre-
ciate the true percentage of patients without infection in
post-hoc analysis. Another study explored the correl-
ation of clinical certainty at the start of antimicrobial
therapy with the post-hoc presence of infection [17].
The primary aim of this latter investigation focused on
antimicrobial use, namely how often administration of
antimicrobials for suspected infection could be justified
by the presence of infection; a large proportion of pa-
tients treated with empirical antibiotics (58 of the 125;
46 %) actually had no infection according to the infec-
tious diseases specialist in the post-hoc assessment [17].
In crude analysis, the likelihood of infection in patients
treated for suspected sepsis was not associated with
mortality. Since several factors that impact on ICU mor-
tality were unequally distributed between groups, we
performed multivariable survival analysis and found that
a lower likelihood of infection was associated with in-
creased mortality. In other words, patients who were
initially treated for sepsis but had, in retrospect, a
Fig. 1 Plausibility of infection stratified by clinical severity upon
presentation in patients with presumed sepsis. Comparison
between the clinical diagnosis of infection at the time of ICU
admission and the actual presence of infection as determined
by post-hoc evaluation
Fig. 2 Plausibility of infection in patients with presumed sepsis upon
presentation for the most frequent sites of infection. Distribution of
plausibility of infection for lung infections (community-acquired
pneumonia and hospital-acquired pneumonia), abdominal infections
(primary and secondary peritonitis), bloodstream infections (primary
bloodstream infections, catheter-related bloodstream infections, and
endocarditis), urinary tract infections, and skin/soft tissue infections
Klein Klouwenberg et al. Critical Care  (2015) 19:319 Page 5 of 8
Infection rate in patients with presumed “sepsis” upon presentation 
Klein Klouwenberg Crit Care 2015;19:319  
Accuracy of sepsis diagnosis 
Ø  Over 50% of patients with suspected pneumonia probably did not had infection 
Ø  Antibiotics are of no use if patients are not infected (harm?) 
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knowledge of pathogen virulence may allow us to implement
therapeutic strategies directed to speciﬁc virulence factors.
As an example, the production of exotoxins from CA-MRSA is
considered a primary virulence mechanism of this organism
in patients with necrotizing pneumonia.29 Based on this
understanding, it has been suggested that blocking protein
synthesis in CA-MRSA may improve patient outcomes.30
A better understanding of the host response may allow us
to manipulate the deleterious immune response that occurs
in some patients with CAP. Immune modulation in hospital-
ized patients with severe CAP through the use of steroids has
been evaluated, but the results remain controversial.31,32
Several retrospective studies have suggested a beneﬁt of
macrolide antibiotics in patients with severe CAP due to their
role as immunomodulators.33–35
The primary approach to improve outcomes in hospital-
ized patients with CAP continues to be the optimal use of
antimicrobials. The literature indicates that optimal antimi-
crobial use in hospitalized patients with CAP requires the
practice of a series of strategies that can be summarized as a
CAP antimicrobial care bundle. In the prevention and man-
agement of health care associated infections, the concept of a
care bundle indicates a set of interventions that, if grouped
and implemented together, promote best outcomes with a
greater impact than if performed individually. The timing of
CAP antimicrobial bundle interventions is summarized
in ►Fig. 6. After a patient arrives at the emergency depart-
ment with signs and symptoms of lower respiratory tract
infection, there is an initial period when the history, physical
examination, laboratory evaluation, and chest x-ray are
obtained. Once the diagnosis of CAP is performed, a full
microbiological workup should be obtained followed by
initiation of antimicrobial therapy. The time between arrival
at the emergency department and delivery of antimicrobials
is deﬁned as the antibiotic timing. Because the literature
indicates that prolonged antibiotic timing is associated with
worse outcomes, initial antibiotics should be administered
soon after the clinical diagnosis of CAP is performed.24 Initial
antimicrobial therapy can be deﬁned as empirical therapy or
targeted therapy. Empirical therapy is performed with broad
spectrum antibiotics that cover the most likely pathogens.
Optimal empirical therapy in regard to antibiotic selection
and dose is recommended by national organizations in most
countries. Empirical therapy in concordance with guidelines
is associated with improved patient survival.36,37 As new
point of care microbiological tests are available to diagnose
the etiology of CAP during the initial patient evaluation, the
possibility of initiating antimicrobial therapy directed to the
pathogen causing CAP is now possible. This approach, using
initial therapywith narrow spectrum antibiotics, is deﬁned as
targeted therapy or pathogen-directed therapy. Targeted
therapy may be associated with decreased antibiotic toxicity,
decreased collateral damage, and decreased development of
colonization or infection with drug-resistant organisms.
The initial dose of antimicrobials should be given in the
emergency department before hospital admission. One im-
portant decision at the time of hospitalization is the site of
hospital care. Patients can be hospitalized to a medical ward
or a medical ICU. Data from the CAPO study indicate that 12%
of hospitalized patients with CAP are admitted directly to the
medical ICU, whereas 5% are admitted to the medical ward
and later transferred to the medical ICU. Mortality for pa-
tients admitted directly to the ICU was 22% compared with
33% for patients admitted to the medical ward and later
transferred to the ICU (p ¼ 0.001). CAPO data suggesting
that delayed ICU admission is associated with increased
mortality have been previously reported by other
investigators.38
After hospitalization, the patient should be evaluated
daily. The day that the patient reaches clinical stability,
intravenous antibiotics can be switched to oral antibiotics,
a practice deﬁned as switch therapy. If results of initial
microbiological cultures deﬁned the etiology of CAP, empiri-
cal broad spectrum therapy should be changed to therapy
directed to the pathogen causing CAP, a practice deﬁned as
deescalation of therapy. Discontinuation of antibiotics can
occur in some patients soon after the patient reaches clinical
stability. The sequential optimal application of the CAP
antimicrobial bundle will allow for a shorter time to clinical
stability, a decreased duration of hospitalization, and im-
proved patient morbidity andmortality. The implementation
of CAP antimicrobial bundles at the local hospital level can be
evaluated with the use of quality indicators. Some aspects of
the CAP antimicrobial bundle are evaluated in the CAPO
international study using quality indicators. Evaluation of a
microbiologicalworkup before initiation of antibiotic therapy
indicates that blood cultures are obtained in 67% of hospital-
ized patients with CAP, and sputum cultures are obtained in
52% of hospitalized patients with CAP. The switch from
intravenous to oral antibiotics on the day that the patient
reaches clinical stability is performed in 46% of the patients.
Several of the CAPO quality indicator data suggest the need to
improve CAP antimicrobial bundle implementation in most
regions of the world.
Clinical Outcomes Weeks after Hospitalization
After hospital discharge, patients with CAP regularly have a
follow-up clinic appointment within 4weeks. During the ﬁrst
month following the diagnosis of CAP, some patients may
Figure 6 Components of the antimicrobial bundle for management of
patients with pneumonia.
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Antibiotics in critically ill patients: a systematic
review of the pharmacokinetics of b-lactams
Joao Gonçalves-Pereira1,2* and Pedro Póvoa1,2
Abstract
Introduction: Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients
admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the
efficacy of b-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory
concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers.
Methods: We performed a full review of published studies addressing the PK of intravenous b-lactam antibiotics
given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed
database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only
English-language articles reporting studies addressing b-lactam antibiotics that had been described in at least five
previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded.
Results: A total of 57 studies addressing six different b-lactam antibiotics (meropenem, imipenem, piperacillin,
cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more
than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl
with creatinine clearance was usually reported. Consequently, in ICU patients, b-lactam antibiotic half-life and T >
MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was
usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised
in critically ill patients with septic shock.
Conclusions: The PK of b-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients.
Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies
of the PK of ICU patients and therapeutic drug monitoring.
Keywords: administration, dosage, b?β?-lactam antibiotics, microdialysis, pharmacodynamics, pharmacokinetics, ICU
Introduction
Infection and sepsis, whether community- or hospital-
acquired, are important causes of morbidity and mortal-
ity in ICU patients [1,2]. Despite all of the research, sep-
sis therapy continues to depend on supportive
management of the different organ dysfunctions and
failures and on specific therapy for infection with timely
and appropriate antibiotics and/or focus control.
The b-lactam antibiotics, because of their large anti-
microbial spectrum and low toxicity, are among the
first-line therapies for critically ill patients, especially
when a Gram-negative infection is suspected. However,
the efficacy of antibiotics is not easily evaluated, since
the clinical response is usually unnoticeable before 48
hours of therapy [3]. Moreover, the unavailability of rou-
tine therapeutic drug monitoring for the great majority
of these drugs makes it difficult to distinguish clinical
failure due to underdosing from lack of in vivo organism
susceptibility.
Considerable evidence demonstrates that free drug
time above bacteria minimal inhibitory concentration (f
T > MIC) is the measure of drug exposure most closely
linked to the ability of b-lactam antibiotics to kill the
target bacteria [4]. T > MIC is dependent on the half-
life (T1/2) of b-lactam antibiotics and their serum
concentration.
* Correspondence: joaogpster@gmail.com
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Introducti n
Infection and sepsis, whether community- or hospital-
acquired, are important causes of morbidity and mortal-
ity in ICU patients [1,2]. Despite all of the research, sep-
sis therapy continues to depend on supportive
management of the different organ dysfunctions and
failures and on specific therapy for infection with timely
and appropriate antibiotics and/or focus control.
The b-lactam antibiotics, because of their large anti-
icrobial spectrum and low toxicity, are among the
first-line therapies for critically ill patients, especially
when a Gram-negative infection is suspected. However,
the efficacy of antibiotics is not easily evaluated, since
the clinical response is usually unnoticeable before 48
hours of therapy [3]. Moreover, the unavailability of rou-
tine therapeutic drug monitoring for the great majority
of these drugs makes it difficult to distinguish clinical
failure due to underdosing from lack of in vivo organism
susceptibility.
Considerable evidence demonstrates that free drug
time above bacteria minimal inhibitory concentration (f
T > MIC) is the measure of drug exposure most closely
linked to the ability of b-lactam antibiotics to kill the
target bacteria [4]. T > MIC is dependent on the half-
life (T1/2) of b-lactam antibiotics and their serum
concentration.
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Bacterial load and mortality 
Rello Chest 2009;136:832 
Rt-PCR positive – 26,3% (36,5% positive BC) 
Septic shock – OR 6.29 
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Abstract
Background: Six hospitals instituted a voluntary, system-wide, pathway for community acquired pneumonia (CAP).
We proposed this study to determine the impact of pathway antibiotics on patient survival, hospital length of stay
(LOS), and total hospital cost.
Methods: Data were collected for adults from six U.S. hospitals with a principal CAP discharge diagnosis code, a
chest infiltrate, and medical notes indicative of CAP from 2005-2007. Pathway and non-pathway cohorts were
assigned according to antibiotics received within 48 hours of admission. Pathway antibiotics included levofloxacin
750 mg monotherapy or ceftriaxone 1000 mg plus azithromycin 500 mg daily. Multivariable regression models
assessed 90-day mortality, hospital LOS, total hospital cost, and total pharmacy cost.
Results: Overall, 792 patients met study criteria. Of these, 505 (64%) received pathway antibiotics and 287 (36%)
received non-pathway antibiotics. Adjusted means and p-values were derived from Least Squares regression
models that included Pneumonia Severity Index risk class, patient age, heart failure, chronic obstructive pulmonary
disease, and admitting hospital as covariates. After adjustment, patients who received pathway antibiotics
experienced lower adjusted 90-day mortality (p = 0.02), shorter mean hospital LOS (3.9 vs. 5.0 days, p < 0.01), lower
mean hospital costs ($2,485 vs. $3,281, p = 0.02), and similar mean pharmacy costs ($356 vs. $442, p = 0.11).
Conclusions: Pathway antibiotics were associated with improved patient survival, hospital LOS, and total hospital
cost for patients admitted to the hospital with CAP.
Background
The Infectious Diseases Society of America (IDSA), in
conjunction with the American Thoracic Society (ATS),
has published guidelines for the empiric treatment of
CAP in adults [1]. Regarding ward patients, these guide-
lines advocate fluoroquinolone monotherapy or combi-
nation therapy with a beta-lactam plus a macrolide [1].
The 2007 guidelines were the first to specify a dose for
one of the fluoroquinolones (i.e., levofloxacin 750 mg
daily) [1]. Though not explicitly stated in the guidelines,
it is known from the pharmacokinetic-pharmacodynamic
(PK-PD) literature that higher daily fluoroquinolone
doses allow for greater antibiotic lung penetration [2].
Theoretically, the use of PK-PD based dosing should
result in additional patient benefits beyond those seen
with previous versions of the guidelines which did not
specify PK-PD based dosing [3]. This study aimed to test
this theory by comparing health and economic outcomes
for CAP patients treated according to a clinical pathway
to those patients not treated according to the pathway.
Methods
The study setting was a six-hospital health-system in
Austin, TX and its surrounding communities. In 2004,
these hospitals began to participate in the Center for Med-
icare and Medicaid Services (CMS) Pneumonia Core Mea-
sures. Staff and quality control personnel discovered
suboptimal compliance with guideline-endorsed initial
antibiotics. Therefore, a multi-disciplinary, disease-state
management team designed and implemented a voluntary,
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each of the five PSI risk classes were as follows: I (15%
vs. 12%), II (44% vs. 34%), III (24% vs. 26%), IV (16% vs.
26%), and V (1% vs. 2%). Pathway and non-pathway
patients were frequently not cultured (42% vs. 39%) or
were culture-negative (44% vs. 51%). When a bacterial
pathogen was identified among pathway and non-path-
way patients, it was most frequently Streptococcus pneu-
moniae (8% vs. 5%), Haemophilus influenzae (2% v .
1%), Staphylococcus aureus (2% vs. 2%), Moraxell cat-
arrhalis (1% vs. 0%), or other (1% vs. %).
Crude 90-day mortality was significantly lower in
patients who received pathway antibiotics versus non-
pathway antibiotics (1.4% vs. 4.5%, p < 0.01). This find-
ing was also statistically significant in an adjusted logis-
tic regression model that included PSI risk class, pati nt
age, heart failure, COPD, and admitting hospital as
covariates (p = 0.02).
Mean hospital LOS (4.9 vs. 6.0 days, p < 0.01) and total
hospital costs ($3,184 vs. $4,168, p < 0.01) were signifi-
cantly less for patients treated with pathway vs. non-
pathway therapies; however, total pharmacy costs ($528
vs. $611, p = 0.12) were similar. Adjusted means and
p-values were derived from Least Squares regression
models that included PSI risk class, patient age, heart fail-
ure, COPD, and admitting hospital as covariates.
Adjusted mean hospital LOS was significantly shorter for
patients treated with pathway vs. non-pathway therapies
(3.9 vs. 5.0 days, p < 0.01) (Figure 1). Adjusted hospital
costs were lower with pathway antibiotics ($2,485 vs.
$3,281, p = 0.02) and adjusted total pharmacy costs were
similar ($356 vs. $442, p = 0.11) (Figure 2). These results
demonstrate that, on average, the pathway resulted in
one day shorter time to hospital discharge and a reduced
total hospital cost of $796 per patient. This represents a
potential difference of 9 lives saved, 287 hospital days
saved, and $228,452 saved if all of the 287 patients in the
non-pathway group had been treated with pathway
antibiotics.
Discussion
This study demonstrates that pathway antibiotics are
associated with improved survival, shorter hospital LOS,
and reduced total hospital cost. This pathway is unique
in that it uses PK-PD dosing. In so doing, this study
goes beyond traditional guideline-concordant studies by
examining antibiotic dose and regimen, rather than anti-
biotic choice alone. Our chief finding was a reduction in
mortality for patients who received pathway antibiotics.
We also observed a decrease in hospital LOS and total
hospital costs in CAP patients treated with pathway
antibiotics, despite similar total pharmacy costs. Redu-
cing LOS may have other benefi s including reduced
Table 1 Patient demographics by initial antibiotic
regimen *, †
Characteristic Pathway Non-Pathway p-value
(n = 505) (n = 287)
Age (yrs), median (IQR) 58 (45-71) 68 (51-81) <0.01
Sex
Male 46% 40% 0.1
Female 54% 60% –
Race
White 68% 71% 0.5
Hispanic 17% 14% –
Black 11% 10% –
Other 4% 5% –
Comorbidities
Neoplastic disease 10% 13% 0.2
Liver disease 6% 8% 0.2
Heart failure 10% 14% 0.06
Cerebrovascular disease 5% 7% 0.4
Diabetes mellitus 24% 21% 0.5
COPD 19% 26% 0.02
Asthma 15% 16% 0.9
Depression 9% 10% 0.5
Social history
Tobacco (smoker) 28% 30% 0.5
Alcohol 16% 15% 0.6
Intravenous drug abuse 3% 3% 0.9
Admitting Service
Medicine 92% 92% 0.9
Other 8% 8% –
* Pathway = levofloxacin 750 mg intravenous or oral daily OR ceftriaxone
1000 mg intravenous plus azithromycin 500 mg intravenous or oral daily OR
either of these antibiotic regimens at higher doses; Non-pathway = these
antibiotics at lower doses OR alternative antibiotics; COPD = chronic
obstructive pulmonary disease.
† The following statistical tests were used: Chi-square (sex, race, individual
comorbidities, social history, and admitting service) and Student’s t-test (age).
5.0
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0.0 1.0 2.0 3.0 4.0 5.0 6.0
HospitalLOS(Days)
NonͲPathway(n=287) Pathway(n=505)
p<0.01
Figure 1 Adjusted least squares mean hospital length of stay
by initial antibiotic regimen*. * The adjusted mean and p-value
were derived from a least squares regression model that included
PSI risk class, patient age, heart failure, chronic obstructive
pulm nary disease, and admitti g h spital as covariates.
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Abstract
Rationale: Continuous infusion of b-lactam antibiotics may
improve outcomes because of time-dependent antibacterial activity
compared with intermittent dosing.
Objectives: To evaluate the efﬁcacy of continuous
versus intermittent infusion in patients with
severe sepsis.
Methods:We conducted a randomized controlled trial in
25 intensive care units (ICUs). Participants commenced on
piperacillin–tazobactam, ticarcillin–clavulanate, or meropenem
were randomized to receive the prescribed antibiotic via
continuous or 30-minute intermittent infusion for the remainder
of the treatment course or until ICU discharge. The primary
outcome was the number of alive ICU-free days at Day 28.
Secondary outcomes were 90-day survival, clinical cure 14 days
post antibiotic cessation, alive organ failure–free days at Day 14,
and duration of bacteremia.
Measurements and Main Results:We enrolled 432 eligible
participants with a median age of 64 years and an Acute Physiology
andChronicHealth Evaluation II score of 20. Therewas nodifference
in ICU-free days: 18 days (interquartile range, 2–24) and 20 days
(interquartile range, 3–24) in the continuous and intermittent groups
(P = 0.38). There was no difference in 90-day survival: 74.3% (156 of
210) and 72.5% (158 of 218); hazard ratio, 0.91 (95% conﬁdence
interval, 0.63–1.31; P = 0.61). Clinical cure was 52.4% (111 of 212)
and 49.5% (109 of 220); odds ratio, 1.12 (95% conﬁdence interval,
0.77–1.63; P = 0.56). There was no difference in organ failure–free
days (6 d; P = 0.27) and duration of bacteremia (0 d; P = 0.24).
Conclusions: In critically ill patients with severe sepsis, there was no
difference in outcomes between b-lactam antibiotic administration
by continuous and intermittent infusion.
Australian New Zealand Clinical Trials Registry number (ACT
RN12612000138886).
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Critically ill septic patient 
Large Volume of Distribution 
•  Large volume 
resuscitation 
•  Invasive Ventilation 
•  Surgical procedure 
Initial High Loading Dose Renal or Hepatic failure 
Yes 
Adjust Dose 
accordingly 
No 
Increased Clearance 
      (measure Cr Clearance) 
•  Vasopressors 
•  ↑ Cardiac output 
•  ↑ Diuresis 
Maintain High Dose 
Reassess after 48-72h 
Any of:  
•  Bacteria with a low MIC 
•  Normalization of (measured) 
Cr Clearance 
•  Sepsis resolution 
Adjust Dose 
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Abstract Considerable evidence has shown that adequate antibiotic therapy is of utmost importance in
the critically ill septic patient. However, antibiotic concentration may be insufficient early in infection
course. We propose the concept of dose modulation, meaning front-line variability of antibiotic dose,
according to patient and microorganism characteristics, followed by its reduction after clinical response
and patient recovery. Therefore, dose modulation means concentrating the largest weight of antibiotics
at the front-end, when the microbial load is higher and the pharmacokinetic changes poses the highest
risk of underdosing and nibbling off antibiotic dose, when the sepsis syndrome is improving, guided by
pharmacokinetic and pharmacodynamic data.
© 2012 Elsevier Inc. All rights reserved.
1. Adequate antibiotic therapy: drug but also
dose selection
The accumulation of evidence that both front-line
antibiotic inappropriateness and late appropriateness had
significant impact on the outcom of infections in severe
sepsis and septic shock patients led to the concept of
antibiotic de-escalation, meaning that a large-spectrum
antibiotic regimen should immediately be started front-line
to assure coverage of the pathogen and clinical success.
Combination antibiotic therapy has also been proposed in
order to enlarge antibacterial spectrum and it may improve
patient outcomes, especially in septic shock patients [1]. In
parallel, antibiotic streamlining should be done as soon as
there is evidence of clinical response and microbiological
results are available, to reduce antibiotic pressure and avoid
the emergence of antimicrobial resistance [2]. This has been
shown to be safe in critically ill patients [3].
Several authors also pointed out that not only should
antibiotic therapy be appropriate and early but also antibiotic
dose should be maximized to ensure adequate bactericidal
concentration as soon as possible [4,5].
However, the concept of dose maximization is ill-defined
and, in our opinion, did not translate into the clinical arena.
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Accumulation and Toxicity 
Ceftriaxone 2 g/d – Increase 2-3* from D1 to D7 
Cr Cl >50 mL/min <50 mL/min 
Day 1 19,5 µg/mL 46,5 µg/mL 
Day7 38,5 µg/mL 125 µg/mL 
Heinemeyer Int Care Med 1990; 16; 448 
 Betalactamin-induced central nervous 
side effects include confusion, disturbances of 
behaviour, hallucinations, asterixis, myoclonic jerks, 
and generalised convulsive or nonconvulsive seizures. 
Those are probably underreported but may 
contribute to morbidity and mortality. 
   Chatellier Int Care Med 2002; 28. 214 
Singer. Plos Med 2005. e167 
F  May promote mitochondrial 
damage and shutdown. 
F  May interfere with mitochondrial 
biogenesis and delay recovery. 
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Table 1. RCTs on Antimicrobial Duration in Typical Infectious Diseases in Adults, Divided by Year of Publication and Type of Infectiona
Investigator
(year, reference)
Type of
infection
Regimen of
shorter course
treatment Regimen of comparator N Outcome
Siegel et al
(1999, [10])
CAP Cefuroxime 750mg q8h IV,
2d, then cefuroxime axetil
500mg q12 PO, 5d, 7d in total
Cefuroxime 750mg q8h IV,
2d, then cefuroxime axetil
500mg q12 PO, 8d, 10d in total
52 No difference in
clinical cure
Leophonte et al
(2002, [11])
CAP Ceftriaxone 1g IV qd, 5d Ceftriaxone 1g IV qd, 10d 244 No difference in
clinical cure
Dunbar et al
(2003, [12])
CAP Levofloxacin 750mg
IV/PO qd, 5d
Levofloxacin 500mg IV/PO qd,
10d
528 No difference in
clinical cure and
bacteriological
outcome
Dunbar et al
(2004, [13])
CAP
atypical
Levofloxacin
750mg IV/PO qd, 5d
Levofloxacin 500mg IV/PO qd,
10d
149 Noninferiority in
clinical cure and
bacteriological
outcome
Leophonte et al
(2004, [14])
CAP Gemifloxacin
320mg qd, 7d
Amoxicillin/clavulanate
1000/125mg, 10d
320 No difference in
clinical, bacteriological,
and radiological efficacy
Tellier et al
(2004, [15])
CAP Telithromycin 800mg
PO qd, 5d
Telithromycin 800mg PO qd, 7d 378 No difference in clinical
cure and bacteriological
outcome
Tellier et al
(2004, [15])
CAP Telithromycin 800mg
PO qd, 5d or 7d
Clarithromycin 500mg PO bid,
10d
559 No difference in clinical
cure and bacteriological
outcome
El Moussaoui et al
(2006, [16])
CAP Amoxicillin 1g IV q6h, 3d Amoxicillin 1g IV q6h, 3d, then
amoxicillin 750mg PO q8h, 5d,
8d in total
119 Noninferiority in clinical
and radiological success
File et al
(2007, [17])
CAP Gemifloxacin 320mg
PO qd, 5d
Gemifloxacin 320mg PO qd, 7d 510 Non-inferiority in clinical,
bacteriological, and
radiological efficacy
Chastre et al
(2003, [18])
VAP 8 d 15 d 401 No difference in mortality
and recurrence. Antibiotic-free
days (13.1 vs. 8.7, P,.001)
Sexton et al
(1998, [19])
IE Ceftriaxone 2g qd 1 gentamicin
3mg/kg qd, 2 weeks
Ceftriaxone 2g qd, 4 weeks 51 No difference in clinical cure
rate and microbiological
eradication
Gleckman et al
(1985, [20])
AP Gentamicin or Tobramycin
1.5–1.75mg/kg q8h IV, 48-72h,
then TMP-SMX 160/800mg bid
PO, 7-8d, 9-11d in total
Gentamicin or Tobramycin
1.5–1.75mg/kg q8h IV, 48-72h,
then TMP-SMX 160/800mg
bid PO, 18-19d, 20-22d in total
54 No difference in clinical
cure rate
Stamm et al
(1987, [21])
AP Ampicillin 500mg q6h PO,
2 weeks
Ampicillin 500mg q6h PO,
6 weeks
27 No difference in clinical
cure rate
Stamm et al
(1987, [21])
AP TMP-SMX 160/800mg q12h
PO, 2 weeks
TMP-SMX 160/800mg q12h
PO, 6 weeks
33 No difference in clinical
cure rate
Jernelius et al
(1988, [22])
AP Pivampicillin/Pivmecillinam
500/400mg tid PO, 7d
Pivampicillin/Pivmecillinam
500/400mg tid PO, 7d, then
250/200mg tid PO, 14d, 21d
in total
77 Bacteriological success:
28% vs. 69% (P 5 .04)
De Gier et al
(1995, [23])
AP Fleroxacin 400mg qd, 7d Fleroxacin 400mg qd, 14d 54 No difference in clinical
cure rate
Talan (2000, [24]) AP Ciprofloxacin 500mg bid, 7d TMP-SMX 160/800mg bid, 14d 255 Clinical cure rate:
96% vs. 83% (P 5 .02)
Klausner et al
(2007, [25])
AP Levofloxacin 750mg qd, 5d Ciplofloxacin 500mg bid, 10d 192 No difference in
clinical cure and
microbiological eradication
Peterson et al
(2008, [26])
AP Levofloxacin 750mg qd, 5d Ciplofloxacin 500mg bid, 10d 1109 Noninferiority in clinical
cure rate and microbiological
eradication
NOTE. AP, acute pyelonephritis; CAP, community acquired pneumonia; IE, infective endocarditis; TMP-SMX, trimethoprim-sulphamethoxazole; VAP,
ventilator-associated pneumonia.
a RCTs of CAP in which azithromycin were employed as a treatment regimen were excluded.
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Table 1. RCTs on Antimicrobial Duration in Typical I fectious Diseases in Adults, Divi ed by Year of Publication and Type of Infectiona
Investigator
(year, reference)
Type of
infe tion
Regimen of
shorter course
treatment Regimen of co parator N Outcome
Siegel et al
(1999, [10])
CAP efuroxime 750mg q8h IV,
2d, then cefuroxime axetil
500mg q12 PO, 5d, 7d in total
Cefuroxime 750mg q8h IV,
2d, then cefuroxime axetil
500mg q12 PO, 8d, 10d in total
52 No difference in
clinical cure
Leophonte et al
(2002, [11])
CAP eftriaxone 1g IV qd, 5d Ceftriaxone 1g IV qd, 10d 244 No difference in
clinical cure
Dunbar et al
(2003, [12])
CAP Levofloxacin 750mg
IV/PO qd, 5d
Levofloxacin 500mg IV/PO qd,
10d
528 No difference in
clinical cure and
bacteriological
outcome
Dunbar et al
(2004, [13])
CAP
atypical
Levofloxacin
750mg IV/PO qd, 5d
Levofloxacin 500mg IV/PO qd,
10d
149 Noninferiority in
clinical cure and
bacteriological
outcome
Leophonte et al
(2004, [14])
CAP Gemifloxacin
320mg qd, 7d
Amoxicillin/clavulanate
1000/125mg, 10d
320 No difference in
clinical, bacter ological,
and radiological efficacy
Tellier et al
(2004, [15])
CAP Telithromycin 800 g
PO qd, 5d
Telithromycin 800 g PO qd, 7d 378 No difference in clinical
cure and bact riological
outcome
Tellier et al
(2004, [15])
CAP Telithromycin 800 g
PO qd, 5d or 7d
Clarithromycin 500 g PO bid,
10d
559 No difference in clinical
cure and bact riological
outcome
El Moussaoui et al
(2006, [16])
CAP Amoxicillin 1g IV q6h, 3d Amoxicillin 1g IV q6h, 3d, then
amoxicillin 750mg PO q8h, 5d,
8d in total
119 Noninferiority in clinical
and radiological success
File et al
(2007, [17])
CAP Gemifloxacin 320mg
PO qd, 5d
Gemifloxacin 320mg PO qd, 7d 510 Non-inferiority in clinical,
bacteriological, and
radiological efficacy
Chastre et al
(2003, [18])
VAP 8 d 15 d 401 No difference in mortality
and recurrence. Antibiotic-free
days (13.1 vs. 8.7, P,.001)
Sexton et al
(1998, [19])
IE Ceftriaxone 2g qd 1 gentamicin
3mg/kg qd, 2 weeks
Ceftriaxone 2g qd, 4 weeks 51 No difference in clinical cure
rate and microbiological
eradication
Gleckman et al
(1985, [20])
AP Gentamicin or Tobramycin
1.5–1.75mg/kg q8h IV, 48-72 ,
then TMP-SMX 160/800mg bid
PO, 7-8d, 9-11d in total
Gentamicin or Tobramycin
1.5–1.75mg/kg q8h IV, 48-72 ,
then TMP-SMX 160/800mg
bid PO, 18-19d, 20-22d in total
54 No difference in clinical
cure rate
Stamm et al
(1987, [21])
AP mpicillin 500mg q6h PO,
2 weeks
Ampicillin 500mg q6h PO,
6 weeks
27 No difference in clinical
cure rate
Stamm et al
(1987, [21])
AP TMP-SMX 160/800mg q12h
PO, 2 weeks
TMP-SMX 160/800mg q12h
PO, 6 weeks
33 No difference in clinical
cure rate
Jernelius et al
(1988, [22])
AP Pivampicillin/Pivmeci li am
500/400mg tid PO, 7d
Pivampicillin/Pivmeci linam
500/400mg tid PO, 7d, then
250/200mg tid PO, 14d, 21d
in total
77 Bacteriological success:
28% vs. 69% (P 5 .04)
De Gier et al
(1995, [23])
AP Fleroxacin 400mg qd, 7d Fleroxacin 400mg qd, 14d 54 No difference in clinical
cure rate
Talan (2000, [24]) AP Ciprofloxacin 500mg bid, 7d TMP-SMX 160/800mg bid, 14d 255 Clinical cure rate:
96% vs. 83% (P 5 .02)
Klausner et al
(2007, [25])
AP Levofloxacin 750mg qd, 5d Ciplofloxacin 500mg bid, 1 d 192 No difference in
clinical cure and
microbiological eradication
Peterson et al
(2008, [26])
AP Levofloxacin 750mg qd, 5d Ciplofloxacin 500mg bid, 1 d 1109 Noninferiority in clinical
cure rate and microbiological
eradication
NOTE. AP, acute pyelonephritis; CAP, community acquired pneumonia; IE, infective endocarditis; TMP-SMX, trimethoprim-sulphamethoxazole; VAP,
ventilator-associated pneumonia.
a RCTs of CAP in which azithromycin were employed as a treatment regimen wer excluded.
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Duration of Antimicrobial Activity 
Reduction of exposure 
3-7 d vs. 7-10 d 
 No difference in outcomes 
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"I see no hope for the future of our people if they are 
dependent on the frivolous youth of today, for they are 
reckless beyond words. When I was young, we were taught to 
be discreet, respectful of elders, but the present youth are 
exceedingly disrespectful and impatient."  
   Hesiod, 700 BC 
